Evaluation of bacterial uptake, antibacterial efficacy against Escherichia coli, and cytotoxic effects of moxifloxacin-loaded solid lipid nanoparticles Cover

.blurhash-client-img { display: none !important; }

Evaluation of bacterial uptake, antibacterial efficacy against Escherichia coli, and cytotoxic effects of moxifloxacin-loaded solid lipid nanoparticles

Archives of Industrial Hygiene and Toxicology

Volume 73 (2022): Issue 4 (December 2022)

By: Merve Eylul Kiymaci , Gizem Ruya Topal, Ozgur Esim, Merve Bacanli, Cansel Kose Ozkan, Onur Erdem, Ayhan Savaser and Yalcin Ozkan

Open Access

|Dec 2022

Figures & Tables

TEM images of SLN1 (a), SLN2 (b), NLC1 (c), and NLC2 (d)

MOX release from nanoparticles

Flow cytometry results (a: blank NPS; b: fluorescein solution; c: SLN1; d: SLN2; e: NLC1; f: NLC2)

Photomicrographs show bacterial uptake of formulations (a: fluorescein solution; b: SLN1; c: SLN2; d: NLC1; e: NLC2)(40× magnification)

Cytotoxic effects of MOX, MOX-free, and MOX-loaded LNPs in RAW 264_7 cells

RAW 264.7 cell viability (%)
	24 h				48 h				72 h
	0.010 µg/mL	0.025 µg/mL	0.05 µg/mL	0.1 µg/mL	0.010 µg/mL	0.025 µg/mL	0.05 µg/mL	0.1 µg/mL	0.010 µg/mL	0.025 µg/mL	0.05 µg/mL	0.1 µg/mL
MOX	88.65±0.09	69.05±0.35	56.48±0.01	43.90±0.03	89.42±0.02	73.98±0.33	59.43±0.02	40.01±0.10	86.62±0.23	83.49±0.08	54.58±0.02	31.93±0.11
SLN1+MOX	81.56±0.26	75.43±0.29	75.92±0.23	74.55±0.23	94.62±0.02	81.95±0.11	71.44±0.03	58.43±0.06	92.13±0.08	91.46±0.34	89.06±0.28	73.70±0.22
SLN1	95.30±0.08	68.91±0.12	62.78±0.25	57.75±0.01	95.75±0.29	91.22±0.05	85.44±0.06	64.09±0.03	87.12±0.27	82.65±0.09	73.35±0.11	69.72±0.17
SLN2+MOX	93.14±0.08	80.42±0.19	66.66±0.46	62.10±0.21	88.73±0.06	77.09±0.12	63.16±0.12	56.05±0.04	92.13±0.08	91.46±0.34	89.06±0.28	73.71±0.22
SLN2	90.98±0.30	86.81±0.12	64.91±0.09	60.60±0.31	96.51±0.22	94.42±0.12	80.82±0.08	68.49±0.22	96.02±0.33	87.31±0.27	69.95±0.09	55.88±0.06
NLC1+MOX	80.46±0.09	81.65±0.18	85.84±0.26	81.47±0.09	88.72±0.09	72.27±0.04	62.23±0.02	51.10±0.15	85.24±0.09	76.56±0.30	73.78±0.09	56.03±0.32
NLC1	89.19±0.13	78.73±0.17	70.83±0.33	53.27±0.04	92.75±0.13	82.93±0.04	63.82±0.09	54.44±0.05	89.70±0.09	80.44±0.08	63.51±0.35	54.76±0.20
NLC2+MOX	78.43±0.31	65.99±0.05	56.58±0.29	50.72±0.04	76.23±0.27	59.40±0.03	53.59±0.06	53.05±0.08	94.10±0.27	79.09±0.03	73.90±0.06	51.68±0.17
NLC2	85.54±0.07	60.58±0.10	56.67±0.26	50.07±0.16	83.62±0.06	62.94±0.12	54.81±0.05	52.27±0.04	91.99±0.42	82.25±0.12	74.99±0.05	54.11±0.09

Lipid nanoparticle properties

LNP	Particle size (nm)	Polydispersity index	Zeta potential (mV)	Encapsulation efficiency (%)
SLN1	181.6±1.27	0.25±0.02	-14.6±0.32	68.61±0.20
SLN2	201.8±1.65	0.29±0.02	-17.5±0.14	74.53±0.34
NLC1	176.8±1.90	0.57±0.23	-11.6±0.61	77.82±0.21
NLC2	132.4±1.62	0.51±0.53	-6.3±0.38	77.17±0.21

Stability of lipid nanoparticles stored for one month at +4 °C

	Particle size (nm)		Polydispersity index		Zeta potential (mV)
Type of LNPs	Baseline value	After one month storage	Baseline value	After one month storage	Baseline value	After one month storage
SLN1	181.6±1.27	186.1±2.89	0.25±0.02	0.36±0.25	-14.6±0.32	-10.0±0.51*
SLN2	201.8±1.65	200.5±3.56	0.29±0.02	0.39±0.12	-17.5±0.14	-11.5±0.45*
NLC1	176.8±1.90	180.3±1.64	0.57±0.23	0.60±0.46	-11.6±0.61	-8.30±0.78
NLC2	132.4±1.62	135.2±3.98	0.51±0.53	0.65±0.22	-6.3±0.38	-5.62±0.96

Composition of lipid nanoparticles

Formulation code	Solid lipid (glyceryl dibehenate)	Liquid lipid (docosahexaenoic acid, DHA)	Liquid lipid (oleic acid)	Tween 80	Poloxamer 407	Triethanolamine (TEA)
SLN1	150 mg	-	-	100 mg	-	-
SLN2	150 mg	-	-	-	100 mg	-
NLC1	110 mg	40 mg	10 mg	-	100 mg	10 mg
NLC2	110 mg	40 mg	-	-	100 mg	10 mg

Antibacterial activity of MOX-loaded SLNs and NLCs

Formulations	Inhibition diameter (mm)	Minimal inhibition concentration (μg/mL)
Standard MOX solution for SLNs * (0.68 mg)	33±0.07	0.041
SLN1	34±0.10***	0.020
SLN2	32±0.11	0.041
Standard MOX solution for NLCs** (0.78 mg)	35±0.08	0.023
NLC1	36±0.12	0.023
NLC2	35±0.05	0.023

DOI: https://doi.org/10.2478/aiht-2022-73-3667 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254

Journal RSS Feed

Language: English, Croatian, Slovenian

Page range: 260 - 269

Submitted on: Jul 1, 2022

Accepted on: Nov 1, 2022

Published on: Dec 30, 2022

Published by: Institute for Medical Research and Occupational Health

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

biocompatibility,

drug resistance,

lipid-based nanoparticles,

RAW 264.7 cell line

Related subjects:

Basic medical science,

Basic medical science, other

© 2022 Merve Eylul Kiymaci, Gizem Ruya Topal, Ozgur Esim, Merve Bacanli, Cansel Kose Ozkan, Onur Erdem, Ayhan Savaser, Yalcin Ozkan, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 73 (2022): Issue 4 (December 2022)Next article